A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Trial Identifier: D419NC00001
Sponsor: MedImmune, LLC
NCTID:: NCT02671435
Start Date: February 2016
Primary Completion Date: October 2021
Study Completion Date: September 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version, part 1-2
English Version, part 3
Spanish Version Part 1-2
Spanish Version Part 3
Korean Version Part 1-2
Korean Version Part 3

Trial Locations

Country Location
AU Blacktown, AU, 2148
AU Clayton, AU, 3168
AU Waratah, AU, 2298
BE Bruxelles, BE, 1200
BE Edegem, BE, 2650
BE Leuven, BE, 3000
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, ON Toronto, ON, CA, M5G 1Z5
ES Barcelona, ES, 08035
ES Madrid, ES, 28027
ES Madrid, ES, 28034
ES Málaga, ES, 29010
ES Pamplona, ES, 31008
ES Sevilla, ES, 41013
FR Marseille CEDEX 5, FR, 13385
FR Nantes CEDEX 1, FR, 44093
GB London, GB, SW2 6JJ
GB Sutton, GB, SM2 5PT
HU Debrecen, HU, 4032
IT Milano, IT, 20141
IT Milano, IT, 20132
KR Seoul, KR, 03080
KR Seoul, KR, 05505
KR Seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 06591
NZ Grafton, NZ, 1023
US, AL Birmingham, AL, US, 35233
US, AZ Scottsdale, AZ, US, 85258
US, CA Duarte, CA, US, 91010
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90089
US, CA Sacramento, CA, US, 95817
US, CA Santa Monica, CA, US, 90404
US, CO Aurora, CO, US, 80045
US, FL Tampa, FL, US, 33612
US, IL Chicago, IL, US, 60611
US, MA Boston, MA, US, 02215
US, MD Baltimore, MD, US, 21231
US, MI Detroit, MI, US, 48202
US, NJ New Brunswick, NJ, US, 08903
US, NY Bronx, NY, US, 10461
US, NY New Hyde Park, NY, US, 11042
US, NY New York, NY, US, 10065
US, RI Providence, RI, US, 02903
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75235
US, TX San Antonio, TX, US, 78229
US, UT Salt Lake City, UT, US, 84112